ArticleVaccine2007
Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.
Article in Vaccine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- A High-Coverage Epitope-Based Vaccine Design for EIAV Envelope Polyprotein Using an Immunoinformatic Approach.Veterinary sciences · 2026Article
- Prospects in Innate Immune Responses as Potential Control Strategies against Non-Primate Lentiviruses.Viruses · 2018Review
- Protective efficacy of centralized and polyvalent envelope immunogens in an attenuated equine lentivirus vaccine.PLoS pathogens · 2015Article
- Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies.Veterinary immunology and immunopathology · 2014Article
- Infection of equine monocyte-derived macrophages with an attenuated equine infectious anemia virus (EIAV) strain induces a strong resistance to the infection by a virulent EIAV strain.Veterinary research · 2014Article
- Lessons in AIDS vaccine development learned from studies of equine infectious, anemia virus infection and immunity.Viruses · 2013Review
- Challenges and proposed solutions for more accurate serological diagnosis of equine infectious anaemia.The Veterinary record · 2013Article
- Article
- Development of a high throughput, semi-automated, infectious center cell-based ELISA for equine infectious anemia virus.Journal of virological methods · 2012Article
- Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease.Vaccine · 2010Article
- Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine.Retrovirology · 2010Article
- An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.Retrovirology · 2009Article
- Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases.Journal of virology · 2009Article
- Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.Journal of virology · 2008Article
- Envelope variation as a primary determinant of lentiviral vaccine efficacy.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
We previously reported that an experimental live-attenuated equine infectious anemia virus (EIAV) vaccine, containing a mutated S2 accessory gene, provided protection from disease and detectable infection after virulent virus (EIAV(PV)) challenge [Li F, Craigo JK, Howe L, Steckbeck JD, Cook S, Issel C, et al. A live-attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 2003;77(13):7244-53; Craigo JK, Li F, Steckbeck JD, Durkin S, Howe L, Cook SJ, et al. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol 2005;79(5):2666-77]. To determine if attenuated EIAV vaccines actually prevent persistent infection by challenge virus, we employed a 14-day dexamethasone treatment of vaccinated horses post-challenge to suppress host immunity and amplify replication levels of any infecting EIAV. At 2 months post-challenge the horses were all protected from virulent-virus challenge, evidenced by a lack of EIA signs and detectable challenge plasma viral RNA. Upon immune suppression, 6/12 horses displayed clinical EIA. Post-immune suppression characterizations demonstrated that the attenuated vaccine evidently prevented detectable challenge virus infection in 50% of horses. These data highlight the utility of post-challenge immune suppression for evaluating persistent viral vaccine protective efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.